Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Bates Website

Susan Bates, M.D.

Selected Publications

1)  Noonan AM, Eisch RA, Liewehr DJ, Sissung TM, Venzon DJ, Flagg TP, Haigney MC, Steinberg SM, Figg WD, Piekarz RL, Bates SE.
Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
Clin. Cancer Res. 19: 3095-104, 2013.
[Journal]
2)  Ierano C, Basseville A, To KK, Zhan Z, Robey RW, Wilkerson J, Bates SE, Scala S.
Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration.
Cancer Biol. Ther. 14: 175-83, 2013.
[Journal]
3)  Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet J, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, Collie NL, Bates SE.
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with a MEK inhibitor.
Blood. [Epub ahead of print], 2013.
[Journal]
4)  Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, Frye R, Woo S, Venzon D, Wright J, Skarulis M, Figg WD, Fojo T, Bates SE, Piekarz RL.
Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers.
Clin. Cancer Res. 2013.
[Journal]
5)  Bakhsheshian J, Hall MD, Robey RW, Herrmann MA, Chen JQ, Bates SE, Gottesman MM.
Overlapping Substrate and Inhibitor Specificity of Human and Murine ABCG2.
Drug Metab. Dispos. 2013.
[Journal]
6)  Fojo AT, Bates SE, Chabner BA.
Clinical trial results: sharing results, speeding discoveries.
Oncologist. 18: 779, 2013.
[Journal]
7)  Fojo T, Bates S.
Mechanisms of resistance to PARP inhibitors--three and counting.
Cancer Discov. 3: 20-3, 2013.
[Journal]
8)  Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT.
Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.
Cell Rep. 3: 277-81, 2013.
[Journal]
9)  Bates SE.
Waking the immune system at last.
Clin. Cancer Res. 19: 996, 2013.
[Journal]
10)  Bates SE.
PFS: the endpoint we love and love to hate.
Clin. Cancer Res. 19: 2606, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 8/12/2013.